Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group

European Journal of Oncology Nursing

Volumn 16, Issue 2, 2012, Pages 172-184

  Edmonds, Kim ^a   Hull, Diana ^b   Spencer Shaw, Andrea ^c   Koldenhof, José ^d   Chrysou, Maria ^e   Boers Doets, Christine ^f   Molassiotis, Alexander ^g  

^a Clinical Trials Institute for Cancer Studies ^*  (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^f Waterland Hospital   (Netherlands)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Adverse event; Altered taste; Diarrhoea; Fatigue; Hand foot skin reaction; Management; Mucositis; Nexavar; Sorafenib; Targeted therapy

Indexed keywords

EID: 84857651429     PISSN: 14623889     EISSN: 15322122     Source Type: Journal    
DOI: 10.1016/j.ejon.2011.05.001     Document Type: Review

References (99)

1. Anderson R., Jatoi A., Robert C., Wood L.S., Keating K., Lacouture M.E. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by multikinase inhibitors (MKIs). Oncologist 2009, 14:291-302.
2. Armes J., Chalder T., ddington-Hall J., Richardson A., Hotopf M. A randomized controlled trial to evaluate the effectiveness of a brief, behaviorally oriented intervention for cancer-related fatigue. Cancer 2007, 110:1385-1395.
3. Arnold R.J., Gabrail N., Raut M., Kim R., Sung J.C., Zhou Y. Clinical implications of chemotherapy-induced diarrhea in patients with cancer. Journal of Supportive Oncology 2005, 3:227-232.
4. Autier J., Escudier B., Wechsler J., Spatz A., Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Archives of Dermatololgy 2008, 144:886-892.
5. Bajetta E., Procopio G., Verzoni E., Catena L., De D.S., Platania M., et al. Renal cell cancer and sorafenib: skin toxicity and treatment outcome. Tumori 2007, 93:201-203.
6. Barbounis V., Koumakis G., Vassilomanolakis M., Demiri M., Efremidis A.P. Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Supportive Care in Cancer 2001, 9:258-260.
7. Nexavar Approved for Liver Cancer in China 2008, Bayer Healthcare Pharmaceuticals, Available at:. http://pharma.bayer.com/scripts/pages/en/news_room/news_room/news_room64.php.
8. Bellmunt J. The Oncologist's View: targeted therapies in advanced renal cell carcinoma. European Urology Supplements 2008, 7:55-62.
9. Benson A.B., Ajani J.A., Catalano R.B., Engelking C., Kornblau S.M., Martenson J.A., et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. Journal of Clinical Oncology 2004, 22:2918-2926.
10. Bhojani N., Jeldres C., Patard J.J., Perrotte P., Suardi N., Hutterer G., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. European Urology 2008, 53:917-930.
11. Bowen J.M., Stringer A.M., Gibson R.J., Yeoh A.S., Hannam S., Keefe D.M. VSL#3 p.obiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biology and Therapy 2007, 6:1449-1454.
12. Cascinu S., Fedeli A., Fedeli S.L., Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. Journal of Clinical Oncology 1993, 11:148-151.
13. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology 2009, 10:25-34.
14. Cherny N.I. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. Journal of Pain and Symptom Management 2008, 36:413-423.
15. Chu D., Lacouture M.E., Fillos T., Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncologica 2008, 47:176-186.
16. Chu D., Lacouture M.E., Weiner E., Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clinical Genitourinary Cancer 2009, 7:11-19.
17. Clark M. Reader seeks clarification on hand-foot skin reaction. Clinical Journal of Oncology Nursing 2008, 12:395.
18. Clarkson J.E., Worthington H.V., Eden O.B. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews CD000978 2003.
19. Comeau T.B., Epstein J.B., Migas C. Taste and smell dysfunction in patients receiving chemotherapy: a review of current knowledge. Supportive Care in Cancer 2001, 9:575-580.
20. Cramp F., Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database of Systematic Reviews 2008, CD006145.
21. de Nijs E.J., Ros W., Grijpdonck M.H. Nursing intervention for fatigue during the treatment for cancer. Cancer Nursing 2008, 31:191-206.
22. Delia P., Sansotta G., Donato V., Frosina P., Messina G., De R.C., et al. Use of probiotics for prevention of radiation-induced diarrhea. World Journal of Gastroenterology 2007, 13:912-915.
23. Delia P., Sansotta G., Donato V., Frosina P., Salatino A., Messina G., et al. Use of probiotics for prevention of radiation-induced diarrhea. Tumori 2007, 93(Suppl. 6).
24. Downing G.M., Kuziemsky C., Lesperance M., Lau F., Syme A. Development and reliability testing of the Victoria bowel performance scale (BPS). Journal of Pain AndSymptom Management 2007, 34:513-522.
25. Dy S.M., Lorenz K.A., Naeim A., Sanati H., Walling A., Asch S.M. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. Journal of Clinical Oncology 2008, 26:3886-3895.
26. Nexavar 200 mg film-coated tablets. Summary of Product Characteristics 2009, Electronic Medicines Compendium, Available at:. http://emc.medicines.org.uk/emc/industry/default.asp?page=displaydoc.asp%26documentid=7577.
27. EONS guidelines implementation toolkit 1-20. Oral Mucositis Guidelines 2005, EONS, Available at:. http://www.cancernurse.eu/documents/EONSClinicalGuidelinesSection4-en.pdf.
28. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine 2007, 356:125-134.
29. Escudier B., Koralewski P., Pluzanska A., Ravaud A., Bracarda S., Szczylik C., et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α vs. placebo/interferon-α as first-line therapy in metastatic renal cell carcinoma. Journal of Clinical Oncology 2007, ASCO meeting proceedings 25, abstract 3.
30. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
31. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Staehler M., et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Journal of Clinical Oncology 2009, 27:3312-3318.
32. Esper P., Gale D., Muehlbauer P. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies. Clinical Journal of Oncology Nursing 2007, 11:659-666.
33. FDA approves new treatment for advanced kidney cancer 2005, FDA, Available at:. http://www.fda.gov/bbs/topics/NEWS/2005/NEW01282.html.
34. FDA approves Nexavar for patients with inoperable liver cancer 2007, FDA, Available at:. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01748.html.
35. Ferrari V., Sgotti D., Amoroso V., Valcamonico F., Grisanti S., Consoli F., et al. Oral mucositis a side effect in tyrosin-kinase inhibitor therapy (sunitinib): the role of assessment of symptoms in evaluation of toxicity. European Journal of Cancer 2009, 195(Suppl. 7).
36. Fillion L., Gagnon P., Leblond F., Gelinas C., Savard J., Dupuis R., et al. A brief intervention for fatigue management in breast cancer survivors. Cancer Nursing 2008, 31:145-159.
37. Gebbia V., Carreca I., Testa A., Valenza R., Curto G., Cannata G., et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993, 4:443-445.
38. Geller R.B., Gilmore C.E., Dix S.P., Lin L.S., Topping D.L., Davidson T.G., et al. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. American Journal of Hematology 1995, 50:167-172.
39. Giralt J., Regadera J.P., Verges R., Romero J., de la Fuente I., Biete A., et al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. International Journal of Radiation Oncology, Biology, Physics 2008, 71(4):1213-1219.
40. Graham S. Incidence and nursing management of hand foot skin reaction in patients treated with oral tyrosine kinase inhibitors for metastatic renal cell carcinoma. Oncology Nursing Forum 2007, 34:2165. abstract.
41. Grunwald V., Heinzer H., Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 2007, 30:519-524.
42. Harris D.J., Eilers J., Harriman A., Cashavelly B.J., Maxwell C. Putting evidence into practice: evidence-based interventions for the management of oral mucositis. Clinical Journal of Oncology Nursing 2008, 12:141-152.
43. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine 2007, 356:2271-2281.
44. Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
45. Hutson T.E., Bellmunt J., Porta C., Szczylik C., Staehler M., Nadel A., et al. Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET. European Journal of Cancer 2010, 46:2432-2440.
46. Ivanyi P., Winkler T., Ganser A., Reuter C., Grünwald V. Novel therapies in advanced renal cell carcinoma. Deutsches Ärzteblatt International 2008, 105:232-237.
47. Janusch M., Fischer M., Marsch W.C., Holzhausen H.J., Kegel T., Helmbold P. The hand-foot syndrome-a frequent secondary manifestation in antineoplastic chemotherapy. European Journal of Dermatology 2006, 16:494-499.
48. Jeejeebhoy K.N. Symposium on diarrhea. 1. Definition and mechanisms of diarrhea. Canadian Medical Association Journal 1977, 116:737-739.
49. Joensuu H., Trent J.C., Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treatment Reviews 2011, 37:75-88.
50. Kane R.C., Farrell A.T., Saber H., Tang S., Williams G., Jee J.M., et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clinical Cancer Research 2006, 12:7271-7278.
51. Keefe D.M., Schubert M.M., Elting L.S., Sonis S.T., Epstein J.B., Raber-Durlacher J.E., et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007, 109:820-831.
52. King C.R. Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses. Oncology Nursing Society News 2006, 21(8 Suppl):57-58.
53. Lacouture M.E. Sorafenib-induced Hand- Foot Skin Reaction Treatment 2009, Identifier:NCT00667589, Available at:. http://clinicaltrials.gov/ct2/show/NCT00667589?term=00667589%26rank=1.
54. Lacouture M.E., Reilly L.M., Gerami P., Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Annals of Oncology 2008, 19:1955-1961.
55. Lacouture M.E., Wu S., Robert C., Atkins M.B., Kong H.H., Guitart J., et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008, 13:1001-1011.
56. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008, 134:379.
57. Lee W.J., Lee J.L., Chang S.E., Lee M.W., Kang Y.K., Choi J.H., et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. British Journal of Dermatology 2009, 161:1045-1051.
58. Lewis S.J., Heaton K.W. Stool form scale as a useful guide to intestinal transit time. Scandinavian Journal of Gastroenterology 1997, 32:920-924.
59. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008, 359:378-390.
60. Lower E.E., Fleishman S., Cooper A., Zeldis J., Faleck H., Yu Z., et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. Journal of Pain and Symptom Management 2009, 38:650-662.
61. Minton O., Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Annals of Oncology 2008, 20:17-25.
62. Mock V. Evidence-based treatment for cancer-related fatigue. Journal of the National Cancer Institute. Monographs 2004, 32:112-118.
63. Mock V., Atkinson A., Barsevick A., Cella D., Cimprich B., Cleeland C., et al. NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 2000, 14:151-161.
64. Mock V., Pickett M., Ropka M.E., Muscari L.E., Stewart K.J., Rhodes V.A., et al. Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Practice 2001, 9:119-127.
65. Molassiotis A., Sylt P., Diggins H. The management of cancer-related fatigue after chemotherapy with acupuncture and acupressure: a randomised controlled trial. Complementary Therapies in Medicine 2007, 15:228-237.
66. Moore S.H. Managing side effects of targeted therapy and ensuring access to treatment. Oncology Nurses 30th Annual Congress 2006, Available at:. http://www.meniscus.com/rcc-targeted-tx/rcc-targeted-tx.pdf.
67. Motzer R.J., Rakhit A., Schwartz L.H., Olencki T., Malone T.M., Sandstrom K., et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clinical Cancer Research 1998, 4:1183-1191.
68. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2009, 27:3584-3590.
69. Mustian K.M., Morrow G.R., Carroll J.K., Figueroa-Moseley C.D., Jean-Pierre P., Williams G.C. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist 2007, 12(Suppl. 1):52-67.
70. Mystakidou K., Katsouda E., Tsilika E., Smyrniotis V., Vassiliou I., Tsiatas M., et al. Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment. Anticancer Research 2006, 26(3B):2325-2328.
71. Common Terminology Criteria for Adverse Events v4.0 (CTCAE) 2009, National Cancer Institute, Available at:. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
72. Fatigue 2010, National Cancer Institute, Available at:. http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf.
73. O'Brien B.E., Kaklamani V.G., Benson A.B. The assessment and management of cancer treatment-related diarrhea. Clinical Colorectal Cancer 2005, 4(6):375-381.
74. Osterlund P., Ruotsalainen T., Korpela R., Saxelin M., Ollus A., Valta P., et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. British Journal Cancer 2007, 97:1028-1034.
75. Oxman A., Guyatt G. Validation of an index of the quality of review articles. Journal of Clinical Epidemiology 1991, 44:1271-1278.
76. Partridge A.H., Avorn J., Wang P.S., Winer E.P. Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute 2002, 94:652-661.
77. Porta C., Paglino C., Imarisio I., Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clinical and Experimental Medicine 2007, 7:127-134.
78. Porta C., Szczylik C. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treatment Reviews 2009, 35:297-307.
79. Portenoy R.K., Itri L.M. Cancer-related fatigue: guidelines for evaluation and management. Oncologist 1999, 4:1-10.
80. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2006, 24:2505-2512.
81. Richardson G., Dobish R. Chemotherapy induced diarrhea. Journal of Oncology Pharmacy Practice 2007, 13:181-198.
82. Rini B.I. Metastatic renal cell carcinoma: many treatment options, one patient. Journal of Clinical Oncology 2009, 27:3225-3234.
83. Rini B.I., Wilding G., Hudes G., Stadler W.M., Kim S., Tarazi J., et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. Journal of Clinical Oncology 2009, 27:4462-4468.
84. Robert C., Mateus C., Spatz A., Wechsler J., Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. Journal of American Academy of Dermatology 2009, 60:299-305.
85. Shepard D.R., Garcia J.A. Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma. Expert Reviews in Anticancer Therapy 2009, 9:795-805.
86. Spazzapan S., Bearz A., Tirelli U. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Annals of Oncology 2004, 15:1576.
87. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology 2010, 28:1061-1068.
88. Stone P. The measurement, causes and effective management of cancer-related fatigue. International Journal of Palliative Nursing 2002, 8:120-128.
89. Surti C. Bayer/Onyx Pharmaceuticals: Nexavar approved for kidney cancer in Japan. Pharmaceutical business review 2008, Available at:. http://www.pharmaceutical-business-review.com/article_feature.asp?guid=0D8C2552%133F5F-4420-9EEF-231B6912C3B7.
90. Sutherland S. Several therapies may prevent or reduce the severity of oral mucositis associated with cancer treatment. Evidence Based Dentistry 2006, 7:104-105.
91. Topkan E., Karaoglu A. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. Oncology 2006, 71:354-360.
92. Viele C.S. Overview of chemotherapy-induced diarrhea. Seminars in Oncology Nursing 2003, 19(4 Suppl. 3):2-5.
93. Wadler S., Benson A.B., Engelking C., Catalano R., Field M., Kornblau S.M., et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. Journal of Clinical Oncology 1998, 16:3169-3178.
94. Weinmann A., Schulze-Bergkamen H., Schuchmann M., Düber C., Otto G., Galle P., et al. Experiences in the treatment of advanced hepatocellular carcinoma (HCC) with sorafenib beyond the SHARP trial - Management of side effects. Zeitschrift für Gastroenterologie 2008, 10.1055/s-2008-1037650.
95. Wood L. Managing the side effects of sorafenib and sunitinib. Community Oncology 2006, 3:558-562.
96. Wood L.S. Targeted therapies for advanced renal cell carcinoma: part II - sorafenib. Oncology Nursing News 2007, 37-38. November/December.
97. Wood L.S., Manchen B. Sorafenib: a promising new targeted therapy for renal cell carcinoma. Clinical Journal of Oncology Nursing 2007, 11:649-656.
98. Wood L.S., Lemont H., Jatoi A., Lacouture M.E., Robert C., Keating K., et al. Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Community Oncology 2010, 7:23-29.
99. Worthington H.V., Clarkson J.E., Eden O.B. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews 2007, CD000978.